Combined treatments were also successful against pediatric preclinical models with low MGMT expression (i.e., GBM2 glioblastoma and Rh28 rhabdomyosarcoma), responsive to temozolomide, and those with a defective homologous recombination, responsive to talazoparib (i.e., KT-10 Wilms tumor). Here, MGMT is linked to rhabdomyosarcoma.